Male Pattern Hair Loss Could Finally Get a New Treatment Approach
My AccountFIND A DOCTORNewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSmileSun CareTreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin ConditionsSkin Lifting and TighteningBodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessFitnessGLP-1sHealthMenopauseNewBeauty RXBEAUTYPASSNewsView All NewsCelebrityNew LaunchesTreatment & FDA NewsIndustry & Retail NewsFaceView All FaceAcneAnti-AgingCelebrityEye CareHyperpigmentationMakeupSensitive SkinSkin CareSmileSun CareTreatmentsView All TreatmentsNeurotoxinsFillersLasers & Energy DevicesMicroneedlingPost-Procedure Skin CareRegenerative AestheticsSkin ConditionsSkin Lifting and TighteningBodyView All BodySkin CareBody SculptingBreastsButtsCelluliteFragranceHands + NailsLegsPregnancyHairView All HairBond RepairCelebrity HairDry HairFrizzy HairGray HairHair ColorHair GrowthHair RepairScalp HealthTips + TutorialsAwardsView All AwardsNB100 Awards16th Annual Beauty Awards2025 NewBeauty Readers’ Choice AwardsShoppingView All ShoppingBeautyReportGift GuidesNewBeauty StorefrontProduct ReviewsWellnessView All WellnessFitnessGLP-1sHealthMenopauseNewBeauty RXLoading…FIND A DOCTORBEAUTYPASS Advertisement Home›NewBeauty RX›Alopecia (Hair Loss) Male Pattern Hair Loss Could Finally Get a New Treatment Approach In a yearlong study, men who stayed on clascoterone continued to see hair growth. Men with male pattern hair loss have had surprisingly few genuinely new treatment options in decades. Now, a topical solution that works differently from anything currently approved has posted strong one-year results, and it could be headed for FDA review soon. Cosmo Pharmaceuticals shared the 12-month data from two phase 3 trials of its clascoterone 5% topical solution, as reported by Dermatology Times. Together, the SCALP 1 and SCALP 2 studies enrolled 1,465 men with mild to moderate androgenetic alopecia (the medical term for male pattern hair loss) at 51 centers across the U.S. and Europe. The company plans to file for FDA approval in early 2027. If cleared, clascoterone would be the first topical androgen receptor inhibitor for androgenetic alopecia and the first new mechanism of action for male pattern hair loss in more than 30 years.